SOHC: Swiss Cancer Institutes presentation & posters

The Swiss Cancer Institute will have four oral presentations and two posters at the Swiss oncology and hematology congress this year in Basel.

Presenter	Study	Title
Session: Oral presentation Clinical solid tumor oncology Wednesday, 19 Nov 2025, 1:45 p.m. - 3:15 p.m., Kairo 1-2
Richard Cathomas	SAKK 06/17	Perioperative chemo-immunotherapy with Durvalumab for operable muscle-invasive urothelial carcinoma: final analysis of the single arm phase II trial SAKK 06/17
Richard Cathomas	SAKK 06/19	Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer: interim analysis of SAKK 06/19 study
Sacha Rothschild	SAKK 16/14	Prognostic role of exosome in patients with stage IIIA(N2) non-small cell lung cancer treated with perioperative durvalumab in addition to neoadjuvant chemotherapy (SAKK 16/14)
Session: Presidential Symposium Wednesday, 19 Nov 2025, 6 p.m. - 7:30 p.m., Boston 1-2 (Winner of: SSMO award clinical solid tumor oncology)
Alexandros Papachristofilou	SAKK 01/10	Single-dose carboplatin and involved-node radiotherapy for seminoma stage IIA/B: long-term follow-up from the international multicenter phase II trial SAKK 01/10
Session: Guided Poster Tour Wednesday, 19 Nov 2025, 7 p.m. - 8:30 p.m., Hall 4.0
Ilaria Colombo	OvCaR	The SAKK OvCaR Registry: First Interim Analysis of a Multicenter Swiss Ovarian Cancer Registry (OvCaR)
Tobias Silzle	Consulting	The Glasgow Prognostic Score adds Prognostic Information in Elderly AML Patients Ineligible for Intensive Treatment Independently from the Molecular RiskProfile – a Retrospective Multicentre Analysis